<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0004818'>Paroxysmal nocturnal hemoglobinuria</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>) is characterized by intravascular <z:mp ids='MP_0010163'>hemolysis</z:mp> leading to <z:hpo ids='HP_0001903'>anemia</z:hpo> and other clinical manifestations </plain></SENT>
<SENT sid="1" pm="."><plain>Transfusions are often required to support <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> at tolerable levels </plain></SENT>
<SENT sid="2" pm="."><plain>A <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> patient with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> was treated with the complement inhibitor eculizumab, followed by concurrent treatment with recombinant human erythropoietin (rHuEpo) </plain></SENT>
<SENT sid="3" pm="."><plain>Eculizumab alone reduced <z:mp ids='MP_0010163'>hemolysis</z:mp>, increased <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> red blood cell (RBC) mass, and decreased transfusions </plain></SENT>
<SENT sid="4" pm="."><plain>Addition of rHuEpo during eculizumab therapy, enhanced erythropoiesis, further increased <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> RBC mass and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> levels, and rendered the patient transfusion independent for more than two years </plain></SENT>
<SENT sid="5" pm="."><plain>These data show that driving erythropoiesis during eculizumab treatment provided further benefit to a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> and underlying <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> </plain></SENT>
</text></document>